Become a Member of the U.S. Alliance of Diabetes Treatment Centers Today!

Welcome to the
U.S. Alliance of Diabetes Treatment Centers

  


Our Mission Statement

The U.S. Alliance of Diabetes Treatment Centers (USADTC) is a multi-disciplinary medical professional membership alliance. We are committed to transparency and the highest ethical standards of care. We are a scientific and educational organization dedicated to promoting the science of clinical diabetes and metabolism for the improvement of patient care and public health. 

About Us

Research

The U.S. Alliance of Diabetes Treatment Centers is gaining momentum. 


We are  finding volunteers for clinical trials for Diabetes Metabolic Restorative Therapy (DMRT). 


We are asking the Administration and Congress for DMRT research funding at the National Institutes of Health and at the Centers for Disease Control and Prevention.


We are engaging with State Diabetes Control Programs to increase state support to increase DMRT access and treatment for diabetic patients.


DMRT is a metabolic pancreas treatment that has shown promising and life-changing results for many Type 1 and Type 2  diabetes patients but remains to be fraught with skepticism and still considered an experimental treatment by many in the medical arena.


Our research will meet the rigorous standards and criteria within the medical and scientific community before being published and we will strive to bring the world definitive protocols and guidelines that will be able to assist providers with well-defined health care decisions.


Education

The U.S. Alliance is educating our current legislators, insurance payers and multi-specialty providers in the healthcare community with systematically developed, evidence-based research that Diabetes Metabolic Restorative Therapy (DMRT) has the ability to slow, stop or reverse the progression of comorbidities in many diabetic patients.  


Science and technology drive health care, with technology increasing the pace of scientific discovery. Innovations in therapies and care models can expand access to care and remove disparities.


 We believe that providers and patients can actively influence healthcare policy.


Our already heavily burdened healthcare system as well as our communities will greatly benefit. 

Support

We support and advocate for Diabetics and their loved ones who deserve better treatment options and care by providing new treatment strategies. 


We strive to help diabetic patients improve their quality of life, achieve their wellness goals, and heal their body to live their best life possible.  

 

Updates from The Hill

U.S. Alliance Washington D.C. Updates

Tuesday, July 18, 2018

Washington D.C.


Updates Coming Soon




Tuesday, June 12, 2018

Washington D.C.  

U.S. Alliance of Diabetes Treatment Centers Chairman of the Board, Jack Lewin MD and Tennessee Board Member Jim Walker held several important meetings in Washington DC this week ON BEHALF OF THE U.S. ALLIANCE OF DIABETES TREATMENT CENTERS seeking Congressional support for continuation of or resumption of CMS/Medicare reimbursement for Diabetes Metabolic Restorative Therapy (DMRT). We were accompanied in our meetings by Bill Signer of the Carmen Group.
 

We had lunch with Congressman Tom Reed R-NY, who is Co-Chair of the Congressional Diabetes Caucus. Reed has personally struggled with Type 2 diabetes, and has a son with Type 1. He understands the issues well and has expressed a interest in supporting our efforts. We believe he will prove to be a strong advocate.
 

We met for the second time with the staff leaders of the Health Education Labor and Pensions (HELP) Committee chaired by Senator Lamar Alexander R-TN, who has also pledged to advocate for us. Jim Walker knows him personally. They feel a much more effective approach than writing letters on our behalf to CMS is to arrange a direct meeting of the Alliance with Seema Verma, Administrator of CMS, to request coverage with evidence development (CED) or a CMS Innovation Center (CMMI) pilot project grant.  Both would provide reimbursement during a typical 12 month period while research and or outcomes data is collected and shared with the agency.
 

We also met with senior staff of Congresswoman Marsha Blackburn R-TN, who organized the meeting after discussing our goals directly with Jim Walker, her friend and constituent. They offered to get others engaged and will support Senator Alexander’s effort to get a top level CMS meeting going.
 

I met briefly later on Wednesday with staff of two other members of the House I know personally to let them know what we’re doing. When the Seema Verma meeting is scheduled, Alliance members who can attend will also want to meet with their own state members of Congress at the same time.
 

We made some great progress on this visit, but there is more to come!  — Jack Lewin MD

News

Research Updates

 Diabetic Macular Edema (DME) and Diabetic Retinopathy Reversal (DRE)


DME is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. 


Evaluation of existing data with DMRT indicates that DME responds quickly.

DRE affects blood vessels in the light-sensitive tissue called the retina. It is the most common cause of vision loss among people with diabetes and the leading cause of vision impairment and blindness among working-age adults.


Hypothesis: DMRT will arrest the progression of these disorders and, to some degree, reverse their impact.


Methodology: Study group will receive standardized DMRT in addition to conventional therapy.


Principal Investigators:

 Neil S. Patel, MD - NYC

Jack lewin, MD - NYC

 

Study Size: 40 Patients + 30 Patient Control Group


Study Time Frame: 6 months with interim report in 3 months


Study Location(s): 

New York City, New York


Endpoints: Retinavues and standard ophthalmological metrics will demonstrate  quantifiable improvement in DME and DRE. 


http://www.amputeecoalition.org/fact_sheets/diabetes_leamp.pdf 


https://www.calpoly.edu/~jgphelan/_Media%20Assets/white%20papers/avoiding amputations.pdf

Past Events

Tuesday, June 12, 2018 | 8:30 AM EST 

Congressman Richard Neal (D-MA) Breakfast


Mr. Neal is the ranking democrat on ways and Means and would become Chairman if the Democrats take over W&M has oversight for CMS Budgets.


DLA Piper, 500 8th Street, NW Room Conference Room 7-Red, Washington DC


__________


Tuesday, June 12, 2018 | 12:00 PM EST

Congressman Tom Reed (R-NY) Lunch


Mr. Reed is a very influential member of the House Committee on Ways & Means and is a member of the Republican Whip team. He is also the Co-Chairman of the Congressional Diabetes Caucus.


116 Club, 234 3rd St., NE,
Washington DC


News

Science Magazine 

by Science News Staff | March 23,2018


President Donald Trump today signed into law a $1.3 trillion spending package that largely rejects deep cuts to research agencies proposed by the White House and, in many cases, provides substantial increases.Here’s a look at some of the top line numbers for key science agencies:

  • The National Institutes of Health (NIH) in Bethesda, Maryland, receives a $3 billion, 8.3% increase to $37 billion. That is well above the increase proposed by either the House of Representatives or the Senate in their versions of the spending bills, and a blunt rejection of the 22% cut proposed by the White House. Included is an additional $414 million for Alzheimer’s disease research, for a total of $1.8 billion, and a $27 million boost, to $543 million, for clinical and translational science funding. The NIH increase is “beyond words, folks,” tweeted Benjamin Corb, director of public affairs at the American Society for Biochemistry and Molecular Biology in Rockville, Maryland.
  • The National Science Foundation in Alexandria, Virginia, would get $7.8 billion, a 3.9% or $295 million increase. 
  • The Department of Energy’s Office of Science in Washington, D.C., would receive $6.26 billion, an $868 million increase. That is roughly a 15% increase, rather than the 15% cut the White House proposed. 
  • A $457 million, 7.9% increase for NASA science programs, to $6.2 billion. The bill increases the agency’s planetary science program by some 21%, or $382 million, to $2.2 billion. Overall, NASA gets $20.7 billion, $1.1 billion above 2017.
  • Spending at the National Oceanic and Atmospheric Administration in Silver Spring, Maryland, would grow by $234 million, to $5.9 billion overall. 
  • The National Institute of Standards and Technology ​in Gaithersburg, Maryland, would get $1.2 billion, $247 million above 2017 levels.
  • The U.S. Geological Survey in Reston, Virginia, gets $1.1 billion, $63 million above 2017 levels. The bill preserves the agency’s eight climate science centers.
  • Research programs at the U.S. Department of Agriculture in Washington, D.C., would grow by $33 million, to $1.2 billion.
  • The budget of the Environmental Protection Agency ​in Washington, D.C., remains flat at $8.1 billion.

Our Members

Our Members are multi-disciplinary physicians, healthcare administrators and healthcare business owners. They may also be nurse practitioners, registered nurses and healthcare practice managers. 


All of our members are engaged and have a continuing professional interest in the research outcomes of Diabetes Metabolic Restorative Therapy (DMRT) in conjunction with utilizing conventional diabetes treatment, including medication management, nutrition and education for their diabetic patients. 


Our Members are committed to the mission, supporting the purposes and objectives of the U.S. Alliance of Diabetes Treatment Centers and contributing their experience, insights and time.


It is the personal responsibility for all of our Members to be held up to the highest degree of professional ethics and personal integrity. 



Benefits of Being a Member

Your membership gives you access to networking opportunities with multi-specialty providers and other Diabetes Metabolic Restorative Therapy (DMRT) providers.


Your membership grants you inclusion and information with regards to:


· Legislative strategies of the Alliance

· Registry concept

· Protocol consistency and effectiveness collaboration

· Research update and progress reports

· USADTC Association business meetings and agendas

· Strategic Plans re: CMS and research objectives


Full Charter membership status confers the privilege of nominating board members, voting and holding a board seat. These memberships are not transferable. 


  Full Charter Members contribute financially by paying annual membership dues.


The Associate Membership is a basic membership requiring no financial dues.


Associate members do not have the privilege of nominating board members, voting or holding a board seat.

How to Become a Member

Send an email request to the Chairman of the Board of the US Alliance of Diabetes Treatment Centers at Jack Lewin M.D.,

 jlewinmd@usadtc.org


Send us a brief bio and reason why you would like to become a member. 


Qualifications will be reviewed and the Board will vote on acceptance. 


If you desire to become a Full Charter Member, your membership dues must be paid for full membership privileges.


If you desire to become an Associate Member no membership dues but in-kind services and collaboration (e.g. Best Practices, Protocol sharing, etc.) will be required.

U.S. Alliance Upcoming Events

Eastern Standard Times

No upcoming events.

Upcoming Research

Retinopathy

Neuropathy Feet

Neuropathy Hands

More to Come

Contact Us

Send Message

Please contact us directly with any questions, comments, or inquiries you may have.

U.S. Alliance of Diabetes Treatment Centers

2825 3rd Avenue, Bronx, New York, New York 10455, United States

(202) 262-6601

Hours

Monday - Friday: 9AM–5PM EST